Dr. Xiangfei "Scott" Cheng is Founder and CEO of HHCC Biotech, Inc.  He is the sole inventor of a U.S. patent-pending wash-free molecular assay technology for rapid, precision molecular analysis. He founded this company to advance the technology toward practical applications in biomedical research, diagnostics, and molecular analysis. .  

He is a seasoned leader with over 25 years of drug development experience across R&D, small molecules, and biologics. His expertise spans target discovery, preclinical studies, translational medicine, regulatory submissions, clinical development, and product launch through commercialization. He has authored more than 90 publications. 

He holds both an M.D. and a Ph.D.  Over the course of his career, he has held executive leadership roles, including Chief Executive Officer (CEO), Chief Medical Officer (CMO), Chief Scientific Officer (CSO), Director, and Senior Vice President (SVP) of Translational Medicine, across organizations ranging from startups to S&P 100 companies. 

Prior to his enterprise leadership career, Dr. Cheng held a faculty role at University of Maryland, driving research in organ transplantation and immunomodulation. He was also actively involved in cancer research at the same university. 

Dr. Cheng specialized in postdoctoral research in Biochemistry and Molecular Biology at Northwestern University, Chicago, USA, under the mentorship of a member of the U.S. National Academy of Sciences (NAS).